Abstract
Plasmacytoid dendritic cells (PDC) are involved in innate immunity by interferon (IFN)- production, and in adaptive immunity by stimulating T cells and inducing generation of regulatory T cells (T-reg). In this study we studied the effects of mammalian target of rapamycin (mTOR) inhibition by rapamycin, a commonly used immunosuppressive and anti-cancer drug, on innate and adaptive immune functions of human PDC. A clinically relevant concentration of rapamycin inhibited Toll-like receptor (TLR)-7-induced IFN- secretion potently (-64%) but TLR-9-induced IFN- secretion only slightly (-20%), while the same concentration suppressed proinflammatory cytokine production by TLR-7-activated and TLR-9-activated PDC with similar efficacy. Rapamycin inhibited the ability of both TLR-7-activated and TLR-9-activated PDC to stimulate production of IFN- and interleukin (IL)-10 by allogeneic T cells. Surprisingly, mTOR-inhibition enhanced the capacity of TLR-7-activated PDC to stimulate naive and memory T helper cell proliferation, which was caused by rapamycin-induced up-regulation of CD80 expression on PDC. Finally, rapamycin treatment of TLR-7-activated PDC enhanced their capacity to induce CD4(+)forkhead box protein 3 (FoxP3)(+) regulatory T cells, but did not affect the generation of suppressive CD8(+)CD38(+)lymphocyte activation gene (LAG)-3(+)T(reg). In general, rapamycin inhibits innate and adaptive immune functions of TLR-stimulated human PDC, but enhances the ability of TLR-7-stimulated PDC to stimulate CD4(+) T cell proliferation and induce CD4(+)FoxP3(+) regulatory T cell generation.
| Original language | Undefined/Unknown |
|---|---|
| Pages (from-to) | 389-401 |
| Number of pages | 13 |
| Journal | Clinical & Experimental Immunology |
| Volume | 174 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2013 |
Research programs
- EMC MM-04-20-01
- EMC MM-04-20-02-A
- EMC MM-04-47-07